Logo image of SPRC

SCISPARC LTD (SPRC) Stock Fundamental Analysis

NASDAQ:SPRC - Nasdaq - IL0010951403 - Common Stock - Currency: USD

0.3179  0 (-0.97%)

Fundamental Rating

1

Overall SPRC gets a fundamental rating of 1 out of 10. We evaluated SPRC against 195 industry peers in the Pharmaceuticals industry. The financial health of SPRC is average, but there are quite some concerns on its profitability. SPRC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SPRC had negative earnings in the past year.
In the past year SPRC has reported a negative cash flow from operations.
In the past 5 years SPRC always reported negative net income.
SPRC had a negative operating cash flow in each of the past 5 years.
SPRC Yearly Net Income VS EBIT VS OCF VS FCFSPRC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

SPRC has a Return On Assets (-49.87%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -63.28%, SPRC is in line with its industry, outperforming 48.72% of the companies in the same industry.
Industry RankSector Rank
ROA -49.87%
ROE -63.28%
ROIC N/A
ROA(3y)-43.65%
ROA(5y)-65.05%
ROE(3y)-61.5%
ROE(5y)-99.8%
ROIC(3y)N/A
ROIC(5y)N/A
SPRC Yearly ROA, ROE, ROICSPRC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SPRC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRC Yearly Profit, Operating, Gross MarginsSPRC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

4

2. Health

2.1 Basic Checks

SPRC does not have a ROIC to compare to the WACC, probably because it is not profitable.
SPRC has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SPRC has more shares outstanding
SPRC has a better debt/assets ratio than last year.
SPRC Yearly Shares OutstandingSPRC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
SPRC Yearly Total Debt VS Total AssetsSPRC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -7.94, we must say that SPRC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SPRC (-7.94) is worse than 68.72% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that SPRC is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, SPRC is in the better half of the industry, outperforming 60.51% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.94
ROIC/WACCN/A
WACC9.04%
SPRC Yearly LT Debt VS Equity VS FCFSPRC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

SPRC has a Current Ratio of 5.36. This indicates that SPRC is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 5.36, SPRC is doing good in the industry, outperforming 73.33% of the companies in the same industry.
SPRC has a Quick Ratio of 5.28. This indicates that SPRC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.28, SPRC is in the better half of the industry, outperforming 73.85% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.36
Quick Ratio 5.28
SPRC Yearly Current Assets VS Current LiabilitesSPRC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

0

3. Growth

3.1 Past

SPRC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.22%, which is quite impressive.
The Revenue for SPRC has decreased by -54.64% in the past year. This is quite bad
EPS 1Y (TTM)36.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-163.64%
Revenue 1Y (TTM)-54.64%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SPRC Yearly Revenue VS EstimatesSPRC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 500K 1M 1.5M 2M 2.5M
SPRC Yearly EPS VS EstimatesSPRC Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SPRC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SPRC Price Earnings VS Forward Price EarningsSPRC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SPRC Per share dataSPRC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SPRC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SCISPARC LTD

NASDAQ:SPRC (6/16/2025, 3:50:47 PM)

0.3179

0 (-0.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-24 2025-04-24
Earnings (Next)N/A N/A
Inst Owners1.1%
Inst Owner Change0%
Ins Owners0%
Ins Owner ChangeN/A
Market Cap3.57M
AnalystsN/A
Price TargetN/A
Short Float %7%
Short Ratio0.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.44
P/tB 0.53
EV/EBITDA N/A
EPS(TTM)-0.81
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.45
OCFYN/A
SpS0
BVpS0.73
TBVpS0.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -49.87%
ROE -63.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.65%
ROA(5y)-65.05%
ROE(3y)-61.5%
ROE(5y)-99.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.36
Quick Ratio 5.28
Altman-Z -7.94
F-Score5
WACC9.04%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-163.64%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-54.64%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y15.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.3%
OCF growth 3YN/A
OCF growth 5YN/A